



69-08 1619 41
Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail (EV 386659657 US) in an envelope
addressed to: Commissioner for Patents, PO Box
1450, Alexandria, VA 22313-1450, on this 7th day of
September 2004.

s/ Pamela Hollander
Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Jonathan EMBLETON, et al.

Group Art Unit: **1614**

Serial No.: **09/091,958**

Examiner: **Z. Fay**

Confirmation No.: **Unknown**

Filed: **June 7, 1999**

For: **OPHTHALMIC TREATMENT**

SEP 14 2004
TECH CENTER 1600/2800

14 2004

FR 1600/2800

Mail Stop: AMENDMENT
Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- | | |
|---|------------------|
| 1. Return Receipt Postcard | 1 postcard; |
| 2. Transmittal of Supplemental Information Disclosure Statement | 2 pages; |
| 3. PTO.SB/08A Form 1449 | 1 page; |
| 4. Copy of Cited Reference | 1 reference; |
| 5. Fee Due | Deposit Account. |

Respectfully submitted,

Angela J. Grayson
Attorney For Applicant
Registration No. 54,136

Date: September 7, 2004

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-8872
Fax: (858) 678-8233



Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 386659657 US) in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 7th day of September 2004.

s/ Pamela Hollander
Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Jonathan EMBLETON, et al.

Serial No.: **09/091,958**

Confirmation No.: **Unknown**

Filed: **June 7, 1999**

For: **OPHTHALMIC TREATMENT**

Group Art Unit: **1614**

Examiner: **Z. Fay**

Mailstop: **Amendment**

Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SEP 14 2004
TECH CENTER 153042300

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b) or 1.97(c)

37 CFR § 1.97(b)

- ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☒ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:


Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☐ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.


Date: September 7, 2004

Respectfully submitted,



Angela J. Grayson
Attorney For Applicant
Registration No. 54,136

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-8872
Fax: (858) 678-8233



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	09/091,958
Filing Date	June 7, 1999
First Named Inventor	Jonathan EMBLETON, et al.
Art Unit	1614
Examiner Name	Z. Fay
Attorney Docket Number	PC30503 / PH-01754

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	FRAUNFELDER, F.T., "Extraocular Fluid Dynamics: How best to apply topical ocular Medication," <i>Tr. Am. Ophth. Soc.</i> , 1976, pp. 457-487, Vol. LXXIV.	

SEP 14 2004

TECH CENTER 1600/2900

EXAMINER:

DATE CONSIDERED:

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.